Get the latest tech news
The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.
A trade group called the Outsourcing Facilities Association filed a lawsuit in a Texas federal court against the FDA, claiming that tirzepatide is still in short supply, and ending the shortage is “abruptly depriving patients of a much-needed treatment and artificially raising drug prices.” In response to the lawsuit, the FDA decided to reevaluate the decision to put tirzepatide on its shortage list; in the meantime, it is permitting some compounding pharmacies to keep making copies of the drug. Kate Knibbs is a senior writer at WIRED, covering the human side of the generative AI boom and how new tech shapes the arts, entertainment, and media industries.
Or read this on Wired